Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 4/20 | 0.36 |
| ▸ | DRD3 | P35462 | 3/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD5 | P21918 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1712822 | 0.90 | CA2 (0.41) | SMN1; SMN2CA12CA1CA2CA14 | |
| SCHEMBL1132630 | 0.86 | KDM4E (0.37) | SMN1; SMN2DRD2DRD3DRD1DRD4 | |
| SCHEMBL7221831 | 0.83 | DRD2 (0.44) | SMN1; SMN2CA12CA1CA2CA14 | |
| SCHEMBL27588817 | 0.83 | SMN1; SMN2 (0.36) | SMN1; SMN2CA12CA1CA2CA14 | |
| SCHEMBL9275010 | 0.81 | ALDH1A1 (0.38) | SMN1; SMN2TSHRDRD2GAAMEN1 | |
| SCHEMBL3230461 | 0.80 | SRC (0.51) | CA1CA2MEN1KMT2ANFE2L2 | |
| SCHEMBL16335527 | 0.80 | SMN1; SMN2 (0.37) | SLC22A12SMN1; SMN2CA12CA1CA2 | |
| SCHEMBL3252726 | 0.80 | HTT (0.46) | CA12CA1CA2CA14CA7 | |
| SCHEMBL30689781 | 0.80 | HTT (0.46) | CA12CA1CA2CA14CA7 | |
| SCHEMBL13384615 | 0.79 | AR (0.47) | SLC22A12GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209451-A1 | HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209451-A1 | HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209451-A1 | HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-08-20 | — | — | US | disclosed |
| EP-1720863-A4 | HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | BAYER PHARMACEUTICALS CORP (US) | 2009-04-22 | — | — | EP | disclosed |
| US-7517878-B2 | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | BAYER PHARAMCEUTICALS CORPORATION (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517878-B2 | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | BAYER PHARAMCEUTICALS CORPORATION (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517878-B2 | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | BAYER PHARAMCEUTICALS CORPORATION (US) | 2009-04-14 | — | — | US | disclosed |
| EP-1720863-A2 | HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | Bayer Pharmaceuticals Corporation (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005086656-A2 | HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20050192294-A1 | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192294-A1 | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | GPR119, GOT2, IAPP | HTR1A 2232/4885ADRA1D 790/4885ADRA1A 564/4885 |
| US-20090209451-A1 | HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | GPR119, GOT2, IAPP | HTR1A 2232/4885ADRA1D 790/4885ADRA1A 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.